|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  |  |  |  | | --- | --- | --- | --- | --- | |  |  |  | **MD Anderson Cohort** | **Georgetown Cohort** | | **Gender** | **Male** | 5-yr survival rate  for NSAID users | 25.0% | 33.4% | |  |  | 5-yr survival rate for NSAID non-users | 10.6% | 21.5% | |  |  | difference in 5-year RMST (months) | 10.8 | 8.2 | |  | **Female** | 5-yr survival rate  for NSAID users | 35.2% | 46.3% | |  |  | 5-yr survival rate for NSAID non-users | 16.1% | 30.8% | |  |  | difference in 5-year RMST (months) | 12.5 | 8.8 | | **Race** | **African American/Black** | 5-yr survival rate  for NSAID users | 22.2% | 36.5% | |  |  | 5-yr survival rate for NSAID non-users | 10.5% | 22.0% | |  |  | difference in 5-year RMST (months) | 9.7 | 9.2 | |  | **Caucasian/Non-Hispanic White** | 5-yr survival rate  for NSAID users | 30.8% | 45.2% | |  |  | 5-yr survival rate for NSAID non-users | 13.2% | 31.9% | |  |  | difference in 5-year RMST (months) | 12.2 | 7.0 | |  | **Hispanic** | 5-yr survival rate  for NSAID users | 27.4% | 49.4% | |  |  | 5-yr survival rate for NSAID non-users | 14.6% | 36.4% | |  |  | difference in 5-year RMST (months) | 9.3 | 5.6 | | **Smoking Status** | **Never smoker** | 5-yr survival rate  for NSAID users | 39.0% | 39.9% | |  |  | 5-yr survival rate for NSAID non-users | 18.9% | 29.1% | |  |  | difference in 5-year RMST (months) | 11.6 | 8.1 | |  | **Former smoker** | 5-yr survival rate  for NSAID users | 27.2% | 62.8% | |  |  | 5-yr survival rate for NSAID non-users | 14.6% | 31.5% | |  |  | difference in 5-year RMST (months) | 10.0 | 11.9 | |  | **Current smoker** | 5-yr survival rate  for NSAID users | 30.0% | 33.4% | |  |  | 5-yr survival rate for NSAID non-users | 13.1% | 21.5% | |  |  | difference in 5-year RMST (month) | 12.1 | 8.2 |   **Supplementary Table 6**: The MD Anderson cohort 5-year survival rate and difference of 5-year restricted mean survival time in months between NSAID users and non-users by gender, race, and smoking status corresponding to **Figure 2**. Comparisons are made to the Georgetown cohort. |